Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315
· Promising clinical results showed clearance of basal cell carcinoma lesions in 4 of 6 patients. · Potential as non-surgical therapeutic approach for basal cell carcinoma, the most common form of cancer in the USOslo, 11 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage biotech using host-defense peptide derived molecules to kill cancer cells and kick start the immune system, announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported lesion clearance data from Part 1 of an ongoing Phase 2 study of